30 year treatment drought breaks for most common form of bladder cancer
The Therapeutic Goods Administration has approved pembrolizumab (KEYTRUDA 200mg, every three weeks) as monotherapy for…
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- Human pancreatic cancer model offers new opportunities for testing drugs
- Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
- Poor brain cancer survival outcomes on the rise
- Oesophageal cancer: 3-D printed stents deliver breakthrough treatment
- Potential therapeutic targets to inhibit colorectal cancer progression
- UK Lockdowns: Significant reduction in new cancer diagnoses
- More than half of cancer survivors have underlying medical conditions associated with severe COVID
- Providing inclusive care for LGBTQ2SPIA cancer patients
